The proprietary name of new bio drug being developed by Hanmi Pharm is listed in INN granted by WHO.

April 16, Hanmi pharm reported that INN ‘efpeglenatide’ and ‘eflapegrastim’ was granted to its new bio drug LAPSCA-Exendin4 (drug for diabetes) and LAPSGCSF (new drug for neutropenia) respectively, and these names will be used globally.

INN (International Nonproprietary Name) is an official name granted by WHO to classify the properties of drugs in compliance with 'WHO INN Naming' guidelines.

First, efpeglenatide for LAPSCA-Exendin4 is a combined word of ef (protein applied with Lapscovery technology) and enatide (word stem of 'exenatide' property). Eflapegrastim for LAPSGCSF is the combined word of ef+la (Long-acting/prolonged duration of medicinal effect) +grastim (word stem of GCSF).

Efpeglenatide (LAPSCA-Exendin4) is GLP-1 family drug for diabetes. It is currently under development with the aim of once-a-month administration and the late phase 2 clinical trial is its last stage. Phase 2 clinical trial on Eflapegrastim (LAPSGCSF) was successfully conducted by US Spectrum and phase 3 clinical trial is about to be started.